Mayo Imaging Classification May Be Useful in Determining the Need for Nephrectomy in ADPKD

Rosenberg, Stephanie; Virmani, Sarthak; Klarman, Sharon; Santovasi, Samantha; Dai, Feng

doi:10.34067/kid.0003902020

Cited by 4 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The identification of urinary metabolites represented the next step in building a biomarker profile, which is necessary for the assessment of ADPKD. Although the Mayo classification for predicting disease progression in ADPKD is widely used [ 84 ], new urinary biomarkers have been shown to be easy to use, inexpensive, and at least as accurate in assessing the disease’s progression, its severity, and responses to treatment [ 60 , 67 ]. Urinary biomarkers may be useful for predicting the variable evolution of ADPKD from cyst growth to ESRD.…”

Section: Discussionmentioning

confidence: 99%

Urinary Biomarkers in Monitoring the Progression and Treatment of Autosomal Dominant Polycystic Kidney Disease—The Promised Land?

Pana,

Stanigut,

Cimpineanu

et al. 2023

Medicina

View full text Add to dashboard Cite

Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disease, and it leads to end-stage renal disease (ESRD). The clinical manifestations of ADPKD are variable, with extreme differences observable in its progression, even among members of the same family with the same genetic mutation. In an age of new therapeutic options, it is important to identify patients with rapidly progressive evolution and the risk factors involved in the disease’s poor prognosis. As the pathophysiological mechanisms of the formation and growth of renal cysts have been clarified, new treatment options have been proposed to slow the progression to end-stage renal disease. Furthermore, in addition to the conventional factors (PKD1 mutation, hypertension, proteinuria, total kidney volume), increasing numbers of studies have recently identified new serum and urinary biomarkers of the disease’s progression, which are cheaper and more easily to dosing from the early stages of the disease. The present review discusses the utility of new biomarkers in the monitoring of the progress of ADPKD and their roles in new therapeutic approaches.

show abstract

Section: Discussionmentioning

confidence: 99%

Urinary Biomarkers in Monitoring the Progression and Treatment of Autosomal Dominant Polycystic Kidney Disease—The Promised Land?

Pana,

Stanigut,

Cimpineanu

et al. 2023

Medicina

View full text Add to dashboard Cite

show abstract

“… 24 , 25 Mayo Clinic in the USA has published a classification based on imaging criteria, TKV adjusted for height (ht/TKV), which may be helpful in determining the need for nephrectomy pre-transplantation. 26 However, there is no professional consensus regarding the timing (pre-/post-transplant), approach (open vs. laparoscopic), unilateral vs. bilateral and simultaneous nephrectomy and RT. 4 Bilateral nephrectomy renders the patient anephric and anuric which impacts the fluid and nutrition management of the patient, and this needs to discussed with the patient prior to nephrectomy.…”

Section: Nephrectomymentioning

confidence: 99%

Surgical Management of Autosomal Dominant Polycystic Kidney Disease: Principles and Current Practice

Shrestha

2023

J Nepal Med Assoc

View full text Add to dashboard Cite

Autosomal dominant polycystic kidney disease is the third most common cause of renal failure with no definitive treatment available that can directly target the development and growth of the cysts. Endeavours are being made to retard the growth of the cysts and preservation of renal function through medical treatment. However, 50% of the autosomal dominant polycystic kidney disease-affected persons develop complications and end-stage renal disease by the age of fifty-five and need surgical intervention for the management of complications, creation of dialysis access and renal transplantation. This review highlights the principles and current practice pertinent to the surgical management of autosomal dominant polycystic kidney disease.

show abstract

Kidney growth progression patterns in autosomal dominant polycystic kidney disease

Pérez-Segovia,

Cojuc-Konigsberg,

Reul-Linares

et al. 2025

Archives of Medical Research

View full text Add to dashboard Cite

Mayo Imaging Classification May Be Useful in Determining the Need for Nephrectomy in ADPKD

Abstract: This is an Early Access article. Please select the PDF button, above, to view it.

Cited by 4 publications

References 8 publications

Urinary Biomarkers in Monitoring the Progression and Treatment of Autosomal Dominant Polycystic Kidney Disease—The Promised Land?

Urinary Biomarkers in Monitoring the Progression and Treatment of Autosomal Dominant Polycystic Kidney Disease—The Promised Land?

Surgical Management of Autosomal Dominant Polycystic Kidney Disease: Principles and Current Practice

Kidney growth progression patterns in autosomal dominant polycystic kidney disease

Contact Info

Product

Resources

About